clinical trial · NCT03659916
Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFIC
Albireo, an Ipsen Company·phase3·completed·n = 116
Progressive Familial Intrahepatic CholestasisA4250 (odevixibat)
brief summary
Open Label Extension Study to evaluate long term safety and persistence of effect of A4250 in children with PFIC.
started
Sep 28, 2018
primary completion
Feb 15, 2024
completion
Dec 2, 2025
last updated
Apr 2, 2026
official title
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of A4250 in Children With Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 2)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol